• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.

    1/30/23 3:30:02 PM ET
    $AYLA
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AYLA alert in real time by email
    15-12G 1 form15-12g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number 001-39279

     

    OLD AYALA, INC.

    (Exact name of registrant as specified in its charter)

     

    Oppenheimer 4

    Rehovot 7670104, Israel

    (857) 444-0553

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    MWE Corporate Services, LLC

    1007 North Orange Street, 10th Floor

    Wilmington, DE 19801

    (302) 485-3907

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Common Stock, par value $0.01 per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

      Rule 12g-4(a)(1) ☒
      Rule 12g-4(a)(2) ☐
      Rule 12h-3(b)(1)(i) ☒
      Rule 12h-3(b)(1)(ii) ☐
      Rule 15d-6 ☐
      Rule 15d-6 ☐

     

    Approximate number of holders of record as of the certification or notice date: One*

     

    * Explanatory Note: On January 19, 2023, the registrant (now known as Old Ayala, Inc., but known at the time as Ayala Pharmaceuticals, Inc.), a Delaware corporation, completed a transaction whereby the registrant became a wholly-owned subsidiary of an entity then known as Advaxis, Inc., a Delaware corporation(which subsequent to such transaction changed its name to Ayala Pharmaceuticals, Inc.). This certification on Form 15 is being filed to suspend the registrant’s duty to file reports, but the registrant intends to file an Annual Report on Form 10-K for the fiscal year ended December 31, 2022 no later than March 31, 2023, which is the only report under the Securities Exchange of 1934 it shall be required to file after the date hereof.

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Old Ayala, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

     

    OLD AYALA, INC.

         
    Date: January 30, 2023 By: /s/ Igor Gitelman
      Name: Igor Gitelman
      Title: Interim Chief Financial Officer

     

     

     

     

     

    Get the next $AYLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AYLA

    DatePrice TargetRatingAnalyst
    12/20/2021$22.00Buy
    Maxim Group
    12/20/2021$18.00Buy
    HC Wainwright & Co.
    11/30/2021$12.00 → $17.00Hold → Buy
    Jefferies
    8/17/2021$27.00 → $25.00Outperform
    Oppenheimer
    7/13/2021$29.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $AYLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Advaxis and Ayala Pharmaceuticals Complete Merger

      REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX:ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the na

      1/19/23 9:37:49 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

      REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place in-person November 16-19 in Vancouver, Canada. The ongoing RINGSIDE Pivotal Phase 2/3 clinical trial is evaluating the investigational new drug AL102, a poten

      11/17/22 8:00:00 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors

      REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI). "We are pleased to begin enrollment in the Phase 3 segment of RINGSIDE, which is a significant milestone in our AL102 development program," said Roni Mamluk, Ph.D., President and Chief Exec

      11/16/22 8:00:00 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Martell Bridget A

      3 - Old Ayala, Inc (0001797336) (Issuer)

      11/1/23 4:04:06 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Orbach Pini

      3 - Old Ayala, Inc (0001797336) (Issuer)

      11/1/23 4:00:56 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Golan Roy

      3 - Old Ayala, Inc (0001797336) (Issuer)

      10/31/23 5:48:50 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    SEC Filings

    See more
    • SEC Form 10-K filed by Ayala Pharmaceuticals Inc.

      10-K - Old Ayala, Inc (0001797336) (Filer)

      3/31/23 6:38:48 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.

      15-12G - Old Ayala, Inc (0001797336) (Filer)

      1/30/23 3:30:02 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets

      8-K - Old Ayala, Inc (0001797336) (Filer)

      1/25/23 4:53:46 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Financials

    Live finance-specific insights

    See more
    • Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

      Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi

      10/19/22 6:30:00 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement

      Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) --  Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggress

      10/19/22 6:30:00 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Ayala Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      12/20/21 7:55:57 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • HC Wainwright & Co. initiated coverage on Ayala Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      12/20/21 6:22:04 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals upgraded by Jefferies with a new price target

      Jefferies upgraded Ayala Pharmaceuticals from Hold to Buy and set a new price target of $17.00 from $12.00 previously

      11/30/21 6:55:03 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Old Ayala, Inc (0001797336) (Subject)

      2/8/23 5:16:37 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.

      SC 13G - Old Ayala, Inc (0001797336) (Subject)

      2/7/23 6:01:50 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Old Ayala, Inc (0001797336) (Subject)

      2/6/23 2:49:38 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary